Immunomic Therapeutics Senior Vice President of R&D to Participate in Bio+Tech Conference

Teri Heiland, Ph.D., Senior Vice President of Research and Development at Immunomic Therapeutics, Inc. will participate in the Cancer Immunotherapeutics panel at the Bio+Tech18 Conference in Baltimore, Maryland. Dr Heiland and panelists from VLP Therapeutics and Avidea Technologies will discuss the future of immuno-oncology research. Immunomic’s nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put Immunomic’s UNiversal Intracellular Targeted Expression (UNITE) investigational platform technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Immunomic’s lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy.

Who: Teri Heiland, Ph.D., Senior Vice President of R&D at Immunomic Therapeutics, Inc.

What: Cancer Immunotherapeutics panel session at Bio+Tech18

When: Tomorrow, Thursday, September 20 at 3:30 p.m. EDT

Where: Hilton Baltimore, 401 West Pratt Street, Baltimore, MD 21201 – Medical Buyer Bureau